financetom
Business
financetom
/
Business
/
TJ Maxx Parent TJX Stock Surges After Earnings: What To Know
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TJ Maxx Parent TJX Stock Surges After Earnings: What To Know
May 22, 2024 9:34 AM

TJX Companies (TJX) stock jumped higher Wednesday after the off-price retailer beat sales and earnings expectations for its fiscal first quarter and raised its outlook for the full year.

In the thirteen weeks ended May 4, the parent company of TJ Maxx, Marshalls, HomeGoods, Homesense and Sierra saw revenue increase 5.9% year-over-year to $12.5 billion. Earnings per share (EPS) were up 22.4% from the year prior to 93 cents.

"I am very pleased with our first-quarter performance," TJX CEO Ernie Herrman said in a statement. “Overall comparable store sales increased 3%, at the high-end of our plan, and both profitability and earnings per share were well above our expectations."

TJX's impressive performance was driven by strong same-store sales in the U.S. across all of its brands and geographies, including 2% combined growth at TJ Maxx, Marshalls and Sierra and 4% collective growth at HomeGoods and Homesense.

"We saw comparable sales growth at every division entirely driven by customer transactions, which underscores the strength of our value proposition," Herrman said. "This also gives us confidence in our ability to gain market share across all of our geographies."

The first-quarter results satisfied analysts' expectations. According to Yahoo Finance, Wall Street had anticipated net sales of $12.5 billion and EPS of $0.87.

As a result of its strong performance in the first quarter, the discount retailer raised its EPS outlook for the full year of fiscal 2025. It now anticipates EPS in the range of $4.03 to $4.09, up from its previous range of $3.94 to $4.02.

"The second quarter is off to a good start and we see numerous opportunities for our business for the balance of the year that we plan to pursue," Herrman said. "Longer term, we are excited about the potential we see to drive customer transactions and sales, capture additional market share, and increase the profitability of TJX."

Where does TJX stock stand with analysts?

Analysts are generally optimistic toward the consumer discretionary stock. According to S&P Global Market Intelligence, the consensus analyst target price for TJX stock is $111.38, representing implied upside of about 7% to current levels. Meanwhile, the consensus recommendation is Buy. 

Speaking for the bulls is William Blair analyst Dylan Carden, who has an Outperform (Buy) rating on TJX stock. "We believe shares continue to offer compelling value from a total return standpoint, with 1.5% dividend yield, in good position to take out roughly 5% of the market cap through buybacks, and steady earnings growth in the high single digits over the next two years," Carden says. 

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Natera Launches Zenith Genomics for Rare Disease Diagnosis
Natera Launches Zenith Genomics for Rare Disease Diagnosis
Mar 12, 2026
08:59 AM EDT, 03/12/2026 (MT Newswires) -- Natera ( NTRA ) said Thursday it has commercially launched its Zenith genomics sequencing assay to improve detection of rare diseases. Zenith genomics offers detection of typically hard to detect features like tandem repeat expansions by using long-read sequencing confirmation for diagnostic clarity, according to the company. Natera ( NTRA ) said genome...
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
Mar 12, 2026
Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia’s novel small-molecule inhibitors PARIS & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. ( KZR ) , a clinical-stage biotechnology company developing novel small...
Kraken Robotics Closes $402.5 Million Public Offering of Subscription Receipts
Kraken Robotics Closes $402.5 Million Public Offering of Subscription Receipts
Mar 12, 2026
08:59 AM EDT, 03/12/2026 (MT Newswires) -- Kraken Robotics ( KRKNF ) said Thursday that its subscription receipts offering raised $402.5 million. The company issued 47.4 million receipts at $8.50 each, which included the full exercise of the over-allotment option. Proceeds will partially fund the cash portion for the $615 million acquisition of Covelya Group, a provider of mission-critical underwater...
York Space Systems Acquires Orbion Space Technology, Further Strengthening Supply Chain with Flight-Proven Spacecraft Capability
York Space Systems Acquires Orbion Space Technology, Further Strengthening Supply Chain with Flight-Proven Spacecraft Capability
Mar 12, 2026
DENVER--(BUSINESS WIRE)-- York Space Systems ( YSS ) , a leading, US-based national defense and commercial prime providing a comprehensive suite of mission-critical solutions, today announced it has acquired Orbion Space Technology (Orbion), a Michigan-based manufacturer of flight-proven electric propulsion systems. The acquisition strengthens York’s integrated space ecosystem and directly supports the strategy the company outlined at the time of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved